Healthcare Stock Skyrockets 1,000%, Crushing Returns from Nvidia, Tesla, and Apple Combined
While tech giants grab headlines, this healthcare dark horse delivers staggering returns that leave market darlings in the dust.
The Unlikely Performer
Forget chasing the usual suspects—this medical sector player proves real growth often hides in plain sight. Surging 1,000% while flashy tech stocks play catch-up.
Numbers Don't Lie
Outpacing Nvidia, Tesla, and Apple combined isn't just impressive—it's a market anomaly that's got Wall Street scrambling for explanations. The kind of return that makes hedge fund managers question their MBAs.
Healthcare's Hidden Edge
While tech burns cash on metaverse fantasies, this company delivers actual products to actual patients. Who knew solving real problems could be so profitable?
Maybe the real bubble isn't in healthcare—it's in our obsession with whatever shiny gadget Silicon Valley dreams up next.
Image source: Getty Images.
Understanding the company
Oncology Institute, started in 2007, provides a range of cancer care. This includes physician care, infusions, and radiation. It also provides pharmacy services and clinical trials.
It aims to provide these services under value-based contracts through which Oncology Institute receives a fee. This arrangement offers savings to insurance companies and patients while putting the onus on Oncology Institute to provide high-quality healthcare in a cost-efficient manner.
The company operates in 16 markets across five states, so it remains small. Nonetheless, it has been growing revenue rapidly. Oncology Institute's second-quarter top line increased 21.5% to $119.8 million.
However, the company continues to lose money. It reported an operating loss under generally accepted accounting principles (GAAP) of $11.2 million, although that's narrower than last year's $16.4 million loss.
Future prospects
Companies that make the U.S. healthcare system more cost-effective and produce better outcomes should be rewarded with high revenue and profit growth. Still, it's unclear when or if Oncology Institute will achieve profitability. With the stock soaring this year, it may have gotten ahead of itself.
